Elsevier Science, Inc.

SHERPA: Unknown

People

  1. Giralt
    Giralt
  2. Noy
    Noy
  3. Abdel-Wahab
    Abdel-Wahab
  4. Hassoun
    Hassoun
  5. Horwitz
    Horwitz
  6. Landau
    Landau
  7. Perales
    Perales
  8. Shah
    Shah
  9. Usmani
    Usmani
  10. Zelenetz
    Zelenetz

Groups

  1. Department of Medicine (22)
  2. Center for Hematologic Malignancies (21)
  3. Hematologic Malignancies, Division of (19)
  4. Lymphoma (9)
  5. Bone Marrow Transplant (7)
  6. Survivorship Research (6)
  7. Tow Center for Developmental Oncology (TCDO) (6)
  8. Epidemiology and Biostatistics (5)
  9. Executive Committee, Center for Hematologic Malignancies (5)
  10. GSK Faculty (5)
Search Within
  1. "The Lancet Haematology"
  2. "Journal article"
Formats
  1. Journal Article (30)
Groups
  1. Department of Medicine (22)
  2. Center for Hematologic Malignancies (21)
  3. Hematologic Malignancies, Division of (19)
  4. Lymphoma (9)
  5. Bone Marrow Transplant (7)
  6. Survivorship Research (6)

More Groups

People
  1. Sergio Giralt (5)
  2. Ariela Noy (3)
  3. Ahmet Dogan (2)
  4. Ai Ni (2)
  5. Anas Younes (2)
  6. Andrew Zelenetz (2)

More People

Years
  1. 2024 (2)
  2. 2023 (3)
  3. 2022 (2)
  4. 2021 (8)
  5. 2020 (5)
  6. 2019 (3)

More Years

Publications
  1. The Lancet Haematology (30)

Results (30)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial
    Journal Article

    Delforge, M.; Patel, K.; Eliason, L.; Dhanda, D.; Shi, L.; Guo, S.; Marshall, T. S.; Arnulf, B.; Cavo, M.; Nooka, A.; more...
    The Lancet Haematology (2024)

    Fulltext@MSK | Save
  • Predicting cytopenias, progression, and survival in patients with clonal cytopenia of undetermined significance: A prospective cohort study
    Journal Article

    Cargo, C.; Bernard, E.; Beinortas, T.; Bolton, K. L.; Glover, P.; Warren, H.; Payne, D.; Ali, R.; Khan, A.; Short, M.; more...
    The Lancet Haematology (2024)

    Fulltext@MSK | Save
  • Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): Final analysis of an open-label, randomised, phase 2 trial
    Journal Article

    Voorhees, P. M.; Sborov, D. W.; Laubach, J.; Kaufman, J. L.; Reeves, B.; Rodriguez, C.; Chari, A.; Silbermann, R.; Costa, L. J.; Anderson, L. D. Jr; more...
    The Lancet Haematology (2023)

    Fulltext@MSK | Save
  • Brentuximab vedotin with AVD for stage II–IV HIV-related Hodgkin lymphoma (AMC 085): Phase 2 results from an open-label, single arm, multicentre phase 1/2 trial
    Journal Article

    Rubinstein, P. G.; Moore, P. C.; Bimali, M.; Lee, J. Y.; Rudek, M. A.; Chadburn, A.; Ratner, L.; Henry, D. H.; Cesarman, E.; DeMarco, C. E.; more...
    The Lancet Haematology (2023)

    Fulltext@MSK | Save
  • Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: A phase 1, dose-finding and expansion study
    Journal Article

    Garcia-Manero, G.; Goldberg, A. D.; Winer, E. S.; Altman, J. K.; Fathi, A. T.; Odenike, O.; Roboz, G. J.; Sweet, K.; Miller, C.; Wennborg, A.; more...
    The Lancet Haematology (2023)

    Fulltext@MSK | Save
  • Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b–2, open-label study
    Journal Article

    Martin, T.; Lin, Y.; Agha, M.; Cohen, A. D.; Htut, M.; Stewart, A. K.; Hari, P.; Berdeja, J. G.; Usmani, S. Z.; Yeh, T. M.; more...
    The Lancet Haematology (2022)

    Fulltext@MSK | Save
  • Individualised dosing of anti-thymocyte globulin in paediatric unrelated allogeneic haematopoietic stem-cell transplantation (PARACHUTE): A single-arm, phase 2 clinical trial
    Journal Article

    Admiraal, R.; Nierkens, S.; Bierings, M. B.; Bredius, R. G. M.; van Vliet, I.; Jiang, Y.; Lopez-Yurda, M.; Versluijs, A. B.; Zwaan, C. M.; Lindemans, C. A.; more...
    The Lancet Haematology (2022)

    Fulltext@MSK | Save
  • Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: A multicentre, single-arm, phase 2 trial
    Journal Article

    Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V. E.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E.; Barnes, J. A.; Hamilton, A. M.; more...
    The Lancet Haematology (2021)

    Fulltext@MSK | Save
  • Camidanlumab tesirine in patients with relapsed or refractory lymphoma: A phase 1, open-label, multicentre, dose-escalation, dose-expansion study
    Journal Article

    Hamadani, M.; Collins, G. P.; Caimi, P. F.; Samaniego, F.; Spira, A.; Davies, A.; Radford, J.; Menne, T.; Karnad, A.; Zain, J. M.; more...
    The Lancet Haematology (2021)

    Fulltext@MSK | Save
  • Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: A single-arm, single-centre, phase 2 trial
    Journal Article

    Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
    The Lancet Haematology (2021)

    Fulltext@MSK | Save